FDA approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer
Basel, 29 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Phesgo ™, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Roche has combined two monoclonal antibodies that can be administered by a single SC injection.“The FDA approval of Phesgo reflects our commitment...
Source: Roche Investor Update - June 29, 2020 Category: Pharmaceuticals Source Type: news
Phase II Trial Finds LuPSMA May be Effective for Men with mCRPC
The results, presented at the 2020 ASCO Virtual Scientific Program, found that in men with metastatic castration resistant prostate cancer who were previously treated with docetaxel, 177Lu-PSMA-617 (LuPSMA) was more active than cabazitaxel. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Carboplatin-Pemetrexed Effective for Elderly Patients With Non-small Cell Lung Cancer Carboplatin-Pemetrexed Effective for Elderly Patients With Non-small Cell Lung Cancer
Carboplatin plus pemetrexed followed by maintenance pemetrexed is an effective alternative to docetaxel monotherapy for elderly patients with advanced nonsquamous non-small cell lung cancer (NSCLC), researchers in Japan report.Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 25, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
FDA accepts Roche ’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer
Basel, 25 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subc utaneous (SC) injection in combination with intravenous (IV) chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer. The BLA for the FDC is based on results from the phase III FeDeriCa study, which demonstrated non-inferior levels of Perjeta in the blood (pharmacokinet ics)...
Source: Roche Investor Update - February 25, 2020 Category: Pharmaceuticals Source Type: news
FDA accepts Roche ’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer
Basel, 25 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subc utaneous (SC) injection in combination with intravenous (IV) chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer. The BLA for the FDC is based on results from the phase III FeDeriCa study, which demonstrated non-inferior levels of Perjeta in the blood (pharmacokinet ics)...
Source: Roche Media News - February 25, 2020 Category: Pharmaceuticals Source Type: news
Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet needs continue...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Armas Pharmaceuticals Adds Four Generic Injectables As First Launches of 2020
MANALAPAN, N.J., Jan. 20, 2020 -- (Healthcare Sales & Marketing Network) -- Armas Pharmaceuticals Inc. (Armas), has begun the new year with launches of four generic injectables: Caffeine Citrate, Docetaxel, Gemcitabine and Verapamil HCI. These products ar... Biopharmaceuticals, Generics, Product Launch Armas Pharmaceuticals, CAFCIT, Taxotere, Gemzar, Verapamil (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 20, 2020 Category: Pharmaceuticals Source Type: news
Docetaxel cost-saving alternative to abiraterone in prostate cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 31, 2019 Category: Drugs & Pharmacology Source Type: news
Company-led drug alert – docetaxel injection 80mg /8ml
Pfizer UK Limited is recalling certain batches of docetaxel injection 80mg /8ml. (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - October 22, 2019 Category: Drugs & Pharmacology Source Type: news
Nivolumab Still Has Edge on Chemo After 4 Years in Advanced NSCLC Nivolumab Still Has Edge on Chemo After 4 Years in Advanced NSCLC
Patients with advanced non-small-cell lung cancer (NSCLC) who are treated with the anti-PD-1 antibody nivolumab continue to have better survival than those given docetaxel after four years, according to pooled data from four CheckMate trials.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - September 3, 2019 Category: Pathology Tags: Hematology-Oncology News Source Type: news
